单克隆抗体靶向治疗大肠癌的研究进展

Advancement in Monoclonal Antibody Targeted Therapy of Colorectal Cancer

大肠癌是最常见的消化道恶性肿瘤之一.已证实,大肠癌肿瘤细胞生长与血管内皮生长因子(VEGF)和表皮生长因子受体(EGFR)的过度表达均有密切的关系,作为VEGF和EGFR单克隆抗体,贝伐单抗、西妥昔单抗、帕尼单抗通过阻断VEGF和EGFR的活性,发挥抗肿瘤的作用,为治疗大肠癌开辟了一条新途径.现就近年来单克隆抗体针对大肠癌的治疗作用的研究进展进行综述.

Colorectal cancer was one of the most common digestive tract malignant tumor.It was confirmed that the overexpression of both vascular endothelial growth factor（VEGF） and epidermal growth factor receptor（EGFR） was critical in colorectal carcinogenesis.Bevacizumab,cetuximab and panitumumab produced a marked effect on resist tumour as monoclonal antibody by obstructing the activities of VEGF and EGFR,which would open up a new path for the treatment of colorectal cancer.Updates on monocolonal antibodies in the treatment of colorectal cancer for the past few years were reviewed in this article.